Cognition Therapeutics financials
$0.9544+1.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$47.8M | -$54.0M | -$50.7M | -$43.6M | -$28.6M |
| Net income | -$23.5M | -$34.0M | -$25.8M | -$21.4M | -$16.2M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.32 | $-0.86 | $-0.86 | $-0.91 | $-3.13 |
| EBITDA | -$47.8M | -$53.9M | -$50.6M | -$43.3M | -$28.5M |
| Operating cash flow | -$24.6M | -$28.5M | -$16.0M | -$18.5M | -$3.6M |
| Free cash flow | -$24.6M | -$28.5M | -$16.2M | -$18.7M | -$3.7M |
| Diluted shares | 72.8M | 39.7M | 30.0M | 23.6M | 5.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $36.8M | $25.0M | $29.9M | $41.6M | $54.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $48.4M | $30.2M | $35.2M | $50.4M | $59.1M |
| Total liabilities | $14.1M | $11.5M | $10.7M | $10.2M | $7.9M |
| Shareholders' equity | $34.3M | $18.8M | $24.5M | $40.2M | $51.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology